CD8+ T-cell responses to EBV are preserved after CD25/71 allodepletion
| . | Donor 1 A2-CLG . | Donor 2 A2-CLG . | Donor 3 A2-CLG . | Donor 4 A2-CLG . |
|---|---|---|---|---|
| Unmanipulated | 0.19% | 0.11% | 0.49% | 0.55% |
| CD25/71 | 0.09% | 0.12% | 0.62% | 0.72% |
| . | Donor 1 A2-CLG . | Donor 2 A2-CLG . | Donor 3 A2-CLG . | Donor 4 A2-CLG . |
|---|---|---|---|---|
| Unmanipulated | 0.19% | 0.11% | 0.49% | 0.55% |
| CD25/71 | 0.09% | 0.12% | 0.62% | 0.72% |
FACS analysis of 4 EBV-seropositive donors in unmanipulated PBMCs or after CD25/71 allodepletion after staining with HLA-A2 EBV pentamer. The percentage of pentamer positive cells in the CD3+/CD8+ lymphocyte gate was expressed as a proportion of the CD8+ cells. EBV, LMP-2–specific HLA-A*0201-CLGGLLTMV (A2-CLG).